Form 4: Atrium Therapeutics Director Reports Stock Transaction
Insider Transaction (Form 4)
Sarah Boyce, a Director of Atrium Therapeutics, Inc., reported a transaction in 126,418 shares of common stock on September 18, 2026.
Summary
- Tax/exercise-price withholding: disposed of 126,418 Common Stock at $8.95 ($1,131,441) on September 18, 2026; holds 138,668 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Sarah Boyce — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-18 | Tax/exercise-price withholding | Common Stock | 126,418 | $9 | $1.1M | 138,668 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-18 | Tax/exercise-price withholding (126,418 shares) |
Keywords
insider transaction, Form 4, RNA, Atrium Therapeutics, Inc., neutral, Sarah Boyce
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.